Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

On Wednesday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97. The post Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 appeared first on Investor's Business Daily.

Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Food and Drug Administration's (FDA's) acceptance for review of a biologics license application (BLA) for V114, an investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults. “This collaboration with Merck is one of the core assets that catalyzed o

Ligand Receives Milestone Payment from Merck

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) to leverage Icagen's unique expertise in small molecule therapeutics targeting transmembrane proteins. This collaboration will utilize the Icagen discovery technology to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases. “We are very pleas

Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen's Discovery Technology to Target Neurological Disorders

Ligand has an interesting business plan that it is executing well. Ligand has three technologies that it calls out as important for its near- to mid-term success.

Ligand: Scalable Growth

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

Ligand (LGND) Up 3.4% Since Last Earnings Report: Can It Continue?

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. Two large multinational pharmaceutical companies with a license to OmniAb have reached clinical-development milestones with their programs. The progress by these companies resulted in a total of $4.5 million in milestone payments being earned by Ligand. In addition, CStone Pharmaceuticals recently

Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabled™ Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients. Ready-to-dilute and room temperature stable, SESQUIENT is the only FDA-approved fosphenytoin that allows point-of-care storage, as w

Ligand's Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients

Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations.

Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2020 Results - Earnings Call Transcript

Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss Estimates

  Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were flat in pre-market trading after the company reported Q3 results.

Recap: Ligand Pharmaceuticals Q3 Earnings

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "Our business is performing very well across the board. We are pleased to be reporting strong third quarter financial resul

Ligand Reports Third Quarter 2020 Financial Results

Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.

What's in Store for Ligand (LGND) This Earnings Season?

CTI BioPharma

Cerecor

IVERIC bio Inc

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long-term approach to its small number of investments, which are focused on companies that have successfully commercialized products and which are in a strong financial position.

4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)

China Biologic Products Holdings

Galapagos

Heron Therapeutics

Illumina

Ionis Pharma

REGENXBIO

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company's role in the manufacturing of Veklury® (remdesivir), Gilead Sciences' antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand's Captisol® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 treatment in the United States. The drug is now widely available i

Ligand's Captisol Technology Plays Key Role in the Manufacture of Gilead's Veklury, the First FDA-Approved COVID-19 Treatment

Caesars Entertainment

eHealth

Our call of the day comes from a fourth-generation money manager who specializes in finding overlooked smaller companies.

Need to Know: Why the time is right for a bet on Caesars and 2 other unloved stocks, says this fourth-generation money manager

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today's virtual Investor Day event its senior management reviewed recent business progress and provided a financial growth outlook. Management also provided updated 2020 financial guidance and introduced a preliminary financial outlook for 2021 to 2023 including 2021 financial guidance, and discussed its three primary technology platforms. A webcast of the event including slides is available here. H

Ligand Provides Highlights from Today's Investor Day Event

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand's CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call. Third Quarter 2020 Earnings Conference Call What:   Ligand conference call to discuss financial results and provide general business updates       Date:   Friday, October 30, 2

Ligand's Third Quarter Financial Results to be Reported October 30th

ASLAN Pharmaceuticals Ltd - ADR

Eli Lilly

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million Deal

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the terms of the agreement, Ligand will retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships. The tra

Ligand to Divest Vernalis Research Operations

CHENGDU, China--(BUSINESS WIRE)--HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research. The acquisition is for the entire issued share capital of Vernalis (R&D) Limited, for $25M in cash. The closing of this transaction is subject to customary conditions and approvals, expected to complete before th

HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery

President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: REGN) and remdesivir, an antiviral treatment from Gilead Sciences (NASDAQ: GILD).

Ligand: The Small Cap Powering Gilead's Remdesivir

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt Foehr, President and Chief Operation Officer Matt Korenberg, Chief Financial Officer Vince Antle, PhD, SVP Technical Operations and Quality Assurance Patrick Lucy, SVP and Chief Business Officer, Protein

Ligand to Host Virtual Investor Day on October 20th

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved. The acquired company will cease trading on the NYSE American under the symbol PFNX effective as of October 1, 2

News for Ligand Pharmaceuticals Stock (LGND)